Project/Area Number |
16K08974
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | Juntendo University |
Principal Investigator |
Tomiki Yuichi 順天堂大学, 医学(系)研究科(研究院), 教授 (40245725)
|
Co-Investigator(Kenkyū-buntansha) |
小見山 博光 順天堂大学, 医学部, 非常勤講師 (30348982)
大永 崇 富山県産業技術研究開発センター, その他部局等, 副主幹研究員 (10416133)
|
Project Period (FY) |
2016-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 血中循環腫瘍細胞 / 大腸癌 / マイクロ流体チップ / リキッドバイオプシー / 腫瘍マーカー / 抗EpCAM抗体 / 転移マーカー / 大腸がん / 血中循環癌細胞 / 治療効果判定因子 / サイズ分画CTCチップ / 癌 / 遺伝学 / トランスレーショナルリサーチ |
Outline of Final Research Achievements |
We developed a CTC detection system to diagnose colorectal cancer (CRC) using blood samples. The system uses the polymeric CTC-chip, a new device for CTC isolation. The high efficiency of CTC chip was assessed with cell suspensions of the CRC cell line. The CTC-chip was used to detect CTCs in blood samples obtained from 13 cases of stage II-IV CRS. On average, the number CTCs/ml were lower in patients with stages II and III CRC than in those with stage IV. In cases with stages II-IV, 92% had CTC per ml, which was higher than the positive rate by the carbo- hydrate antigen 19-9 test (CA19-9). Moreover, CTCs were detected in all cases with stage II and III CRC, including cases with negative results for the carcinoembryonic antigen (CEA) and CA19-9 tests. With the CTC-chip detection system, CTCs can be effective cancer markers, particularly for patients in stage II and III CRC who often exhibit negative conventional serum marker test results.
|
Academic Significance and Societal Importance of the Research Achievements |
大腸癌は早期診断により治療効果が高まること、また再発発生の場合も早期対応にて最適治療を行うことができる。今回開発したCTCチップで大腸癌の血中腫瘍細胞を捕捉・同定・計測する方法により、CTCが鋭敏な腫瘍マーカーとして機能し、大腸癌の採血検体による鋭敏な診断が可能になるであろう。またCTC濃度検出によって、癌の進行の検出を容易にすることからも、臨床上の意義は大きい。
|